Since pCR is infrequently achieved in HR+/HER2- breast cancer and its association with outcome is not as strong as in other breast cancer subtypes [3], pCR is not a good primary endpoint for neoadjuvant trials in this breast cancer subtype. Here, ERBB2 is linked to breast cancer.